H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Moleculin Biotech today and set a price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sara Nik’s rating is based on several compelling factors. Firstly, the acceleration in recruitment for the Phase 3 MIRACLE study of annamycin in relapsed or refractory acute myeloid leukemia (r/r AML) patients highlights the significant unmet need in this area. Moleculin Biotech’s strategic global expansion of study sites, including new locations in Spain, Georgia, Poland, and the US, is expected to enhance recruitment efforts, keeping the company on track for a data readout in the fourth quarter of 2025. This proactive approach demonstrates the company’s commitment to meeting its recruitment timelines and advancing its lead asset towards potential regulatory approval.
Additionally, promising preclinical data presented by Moleculin Biotech at the Shelby-Lavine Pancreatic Cancer Symposium underscores the potential of annamycin beyond AML. The data revealed significant efficacy of annamycin against various liver cancers, such as hepatocellular carcinoma and pancreatic ductal adenocarcinoma liver metastases. With its favorable cardiotoxicity profile, annamycin’s potential application in broader oncology indications further strengthens its therapeutic promise. These factors collectively support Sara Nik’s Buy rating for Moleculin Biotech’s stock.
In another report released on September 3, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.